Astellas Pharma
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 1 | ×1.50 | 3 |
Strategy profile
Based on 15 disclosed transactions, Astellas Pharma concentrates its licensing activity in Oncology, Ophthalmology, and Neurology. Astellas Pharma pays a 1.50x premium over market median. Their most common deal structure is Collaboration, with an average disclosed value of $1.8B. Most recent activity: 2026.
Pipeline coverage & gaps
Astellas Pharma has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 5 | $182M | $1.5B |
| LicensePrimary | 5 | $125M | $1.2B |
| Acquisition | 3 | $3.9B | $4.0B |
| Option | 2 | $38M | $1.1B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | isaralgagene civaparvovec (ST-920) | Sangamo Therapeutics, Inc. | fabry disease | phase_1 | $25M | $50M |
| 2026 | — | CytomX Therapeutics | solid tumors | preclinical | $80M | $1.7B |
| 2026 | VIR-5500 | Vir Biotechnology | prostate cancer | phase_1 | $335M | $1.7B |
| 2025 | CLDN18.2 ADC | Evopoint Biosciences | — | phase_1 | $130M | $1.5B |
| 2025 | XNW-27011 | Evopoint | CLDN18.2-positive cancers | unknown | $130M | $1.3B |
| 2025 | CLDN18.2 ADC | Evopoint | oncology | unknown | — | $1.5B |
| 2024 | STAC-BBB capsid (neuro gene therapy) | Sangamo Therapeutics | Undisclosed neurological diseases | preclinical | $20M | $1.3B |
| 2024 | atopicderm | Connect Biopharma | atopicderm | phase_2 | $25M | $350M |
| 2023 | cardiomyopathy | BridgeBio Pharma | cardiomyopathy | phase_3 | $400M | $1.7B |
| 2023 | frontotemporal dementia | AviadoBio | frontotemporal dementia | phase_1 | $50M | $2.2B |
| 2023 | P-MUC1C-ALLO1 | Poseida Therapeutics | multiple solid tumors including breast, ovarian, colorectal, lung, pancreatic and renal carcinomas | phase_1 | $25M | $50M |
| 2023 | R100 vector (rare ophtho GT) | 4D Molecular Therapeutics | Rare retinal diseases | preclinical | $50M | $963M |
| 2023 | avacincaptad pegol (IZERVAY) | Iveric Bio | dryAmdGA | phase_3 | $5.9B | $5.9B |
| 2023 | Araris ADC platform | Evotec (Araris platform) | solid tumors including breast cancer | discovery | — | $1.5B |
| 2023 | avacincaptad pegol (Izervay) | Iveric Bio | geographic_atrophy | approved | $5.9B | $5.9B |
How this is computed
For each Astellas Pharma deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 6 disclosed deal premiums vs. peer medians. Raw premium 1.748, clamped to [0.7, 1.5].